Disturbed bowel habits in patients with non-ulcer dyspepsia

Alimentary Pharmacology and Therapeutics

Volumn 24, Issue 2, 2006, Pages 405-410

  Hammer, J ^a   Talley, N J ^b,c  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b Mayo Clinic College of Medicine   (United States)

^c UNIVERSITY OF SYDNEY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

GASTROINTESTINAL AGENT; SEROTONIN RECEPTOR;

ADULT; AGED; ARTICLE; COLON DISEASE; CONSTIPATION; DEFECATION DISORDER; DEFECATION HABIT; DIAGNOSTIC VALUE; DIARRHEA; DYSPEPSIA; ENTEROPATHY; EVALUATION; FEMALE; GASTROESOPHAGEAL REFLUX; HUMAN; INTESTINE MOTILITY; MAJOR CLINICAL STUDY; MALE; PREVALENCE; PRIORITY JOURNAL; SYMPTOMATOLOGY; VALIDATION PROCESS;

ADULT; CONSTIPATION; DIARRHEA; DYSPEPSIA; FEMALE; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL AGENTS; GASTROINTESTINAL TRANSIT; HUMANS; MALE; MIDDLE AGED; SEROTONIN AGONISTS; SEROTONIN RECEPTOR AGONISTS;

EID: 33745649557     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2006.02992.x     Document Type: Article

References (26)

1. Talley NJ, Stanghellini V, Heading RC, Koch KL, Malagelada JR, Tytgar GNJ. Functional gastroduodenal disorders. Gut 1999; 45 (Suppl. 2): II37-42.
2. Talley NJ, Zinsmeister AR, Schleck CD, Melton LJ III. Dyspepsia and dyspepsia subgroups: a population-based study. Gastroenterology 1992; 102: 1259-68.
3. Whitehead WE, Gibbs NA, Li Z, Drossman DA. Is functional dyspepsia just a subset of the irritable bowel syndrome? Baillieres Clin Gastroenterol 1998; 12: 443-61.
4. Agreus L, Svardsudd K, Nyren O, Tibblin G. Irritable bowel syndrome and dyspepsia in the general population: overlap and lack of stability over time. Gastroenterology 1995; 109: 671-80.
5. Talley NJ, Dennis EH, Schettler-Duncan VA, Lacy BE, Olden KW, Crowell MD. Overlapping upper and lower gastrointestinal symptoms in irritable bowel syndrome patients with constipation or diarrhea. Am J Gastroenterol 2003; 98: 2454-9.
6. Caballero-Plasencia AM, Valenzuela-Barranco M, Herrerias-Gutierrez JM, Esteban-Carretero JM. Altered gastric emptying in patients with irritable bowel syndrome. Eur J Nucl Med 1999; 26: 404-9.
7. Trimble KC, Farouk R, Pryde A, Dougla S, Heading RC. Heightened visceral sensation in functional gastrointestinal disease is not site-specific. Evidence for a generalized disorder of gut sensitivity. Dig Dis Sci 1995; 40: 1607-13.
8. Tack J, Bisschops R, Sarnelli G. Pathophysiology and treatment of functional dyspepsia. Gastroenterology 2004; 127: 1239-55.
9. Thumshirn M, Coulie B, Camilleri M, Zinsmeister AR, Burton DD, Van Dyke C. Effects of alosetron on gastrointestinal transit time and rectal sensation in patients with irritable bowel syndrome. Aliment Pharmacol Ther 2000; 14: 869-78.
10. Prather CM, Camilleri M, Zinsmeister AR, McKinzie S, Thomforde G. Tegaserod accelerates orocecal transit in patients with constipation-predominant irritable bowel syndrome. Gastroenterology 2000; 118: 463-8.
11. Degen L, Matzinger D, Merz M, et al. Tegaserod, a 5-HT4 receptor partial agonist, accelerates gastric emptying and gastrointestinal transit in healthy male subjects. Aliment Pharmacol Ther 2001; 15: 1745-51.
12. Talley NJ, Van Zanten SV, Saez LR, et al. A dose-ranging, placebo-controlled, randomized trial of alosetron in patients with functional dyspepsia. Aliment Pharmacol Ther 2001; 15: 525-37.
13. Miller DP, Alfredson T, Cook SF, Sands BE, Walker AM. Incidence of colonic ischemia, hospitalized complications of constipation, and bowel surgery in relation to use of alosetron hydrochloride. Am J Gastroenterol 2003; 98: 1117-22.
14. Tack J, Vos R, Janssens J, Salter J, Jauffret S, Vandeplassche G. Influence of tegaserod on proximal gastric tone and on the perception of gastric distension. Aliment Pharmacol Ther 2003; 18: 1-7.
15. Hammer J, Eslick GD, Howell SC, Altiparmak E, Talley NJ. Diagnostic yield of alarm features in irritable bowel syndrome and functional dyspepsia. Gut 2004; 53: 666-72.
16. Talley NJ, Phillips SF, Melton LJ III, Wiltgen Ch, Zinsmeister AR. A patient questionnaire to identify bowel disease. Ann Intern Med 1989; 111: 671-4.
17. Drossman DA. The functional gastrointestinal disorders and the Rome II process. Gut 1999; 45 (Suppl. II): II1-5.
18. Talley NJ, Vakil N. Guidelines for the management of dyspepsia. Am J Gastroenterol 2005; 100: 2324-37.
19. Tanum L, Malt UF. A new pharmacologic treatment of functional gastrointestinal disorder. A double-blind placebo-controlled study with mianserin. Scand J Gastroenterol 1996; 31: 318-25.
20. Balfour JA, Goa KL, Perry CM. Alosetron. Drugs 2000; 59: 511-8.
21. Olden KW, Crowell MD. Cilansetron. Drugs Today (Barc) 2005; 41: 661-6.
22. Camilleri M. Safety concerns about alosetron. Arch Intern Med 2002; 162: 100-1.
23. Evans BW, Clark WK, Moore DJ, Whorwell PJ. Tegaserod for the treatment of irritable bowel syndrome. Cochrane Database Syst Rev 2004; 1: CD003960.
24. Talley NJ, Weaver AL, Tesmer DL, Zinsmeister AR. Lack of discriminant value of dyspepsia subgroups in patients referred for upper endoscopy. Gastroenterology 1993; 105: 1378-86.
25. Drossman DA, Camilleri M, Mayer EA, Whitehead WE. AGA technical review on irritable bowel syndrome. Gastroenterology 2002; 123: 2108-31.
26. McKee DP, Quigley EM. Intestinal motility in irritable bowel syndrome: is IBS a motility disorder? Part 2. Motility of the small bowel, esophagus, stomach, and gall-bladder. Dig Dis Sci 1993; 38: 1773-82.